Evaxion Biotech A/S
NASDAQ:EVAX
Evaxion Biotech A/S
Net Income (Common)
Evaxion Biotech A/S
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Evaxion Biotech A/S
NASDAQ:EVAX
|
Net Income (Common)
-$22.1m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
Genmab A/S
CSE:GMAB
|
Net Income (Common)
kr4.4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
24%
|
CAGR 10-Years
44%
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Net Income (Common)
-kr703.7m
|
CAGR 3-Years
6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-14%
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Net Income (Common)
-€501.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Net Income (Common)
kr1.5B
|
CAGR 3-Years
75%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Bioporto A/S
CSE:BIOPOR
|
Net Income (Common)
-kr56.3m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
See Also
What is Evaxion Biotech A/S's Net Income (Common)?
Net Income (Common)
-22.1m
USD
Based on the financial report for Dec 31, 2023, Evaxion Biotech A/S's Net Income (Common) amounts to -22.1m USD.
What is Evaxion Biotech A/S's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-32%
Over the last year, the Net Income (Common) growth was 5%. The average annual Net Income (Common) growth rates for Evaxion Biotech A/S have been -14% over the past three years , -32% over the past five years .